

## Special Issue

# Advances in DNA Vaccine Research

### Message from the Guest Editor

Recently, DNA vaccines have emerged as a promising method for preventing and controlling diseases. They consist of a plasmid with a DNA sequence encoding a target protein or antigen that activates the host's immune response. DNA vaccines offer many advantages, including increased stability, easy scalability and production, lack of any infectious agents, safe storage and easy handling, while also inducing both cellular and cell-mediated immunity. Additionally, the efficacy of DNA vaccines can be further enhanced by vehicles that help the contents of DNA vaccines enter specific cells. However, further research is needed to fully understand the immune response induced by DNA vaccines and its mechanisms. In this Special Issue, we welcome original research articles and reviews in the following areas:

- DNA vaccines;
- Methods for DNA vaccine production;
- Methods for DNA vaccine delivery;
- Vector design for DNA vaccines;
- Vaccine insert design;
- Adjuvants for DNA vaccines;
- DNA vaccine delivery;
- Immune response induced by DNA vaccines;
- Applications of DNA vaccines;
- Plasmid-based vaccines;
- Advantages of DNA vaccines;
- DNA vaccine formulations.

### Guest Editor

Dr. Dabbu Jaijyan

Department of Anatomy and Neurobiology, Virginia Commonwealth University, Richmond, Virginia, USA

### Deadline for manuscript submissions

28 February 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/213945](https://mdpi.com/si/213945)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).